Dyadic International (NASDAQ:DYAI) has engineered its C1-cell protein production platform to demonstrate the potential of manufacturing therapeutically viable and commercially useful cannabis compounds, including cannabidiol (CBD) and its precursors, using synthetic biology.
C1-cells have the potential to be an easy way to produce pure synthetic cannabinoids for commercial use, cheaper and more effectively, compared with conventional extraction methods utilizing hemp and the marijuana plant.
“For the consumer, the potential benefits are high-quality, low-cost CBD, other forms of cannabinoids and THC. You can get exactly what you want from the C1-cells,” Dr. Ronen Tchelet, Dyadic’s CSO, said in a statement.
“Filamentous fungal cell factories are expected to be more environmentally friendly and less energy intensive than growing the plant and separating out the psychoactive and non-psychoactive ingredients,” he added. “They may also yield cannabinoid derivatives with unexpected medical uses.”
Dyadic’s synthetic biology cannabinoid C1 production process has the potential to develop commercially viable biological methods of producing CBD, such as cannabigerolic acid, cannabigerovarinic acid, tetrahydrocannabinolic acid, cannabidiolic acid, and cannabidivarinic acid.
“We are excited to introduce a novel synthetic production method of producing CBD and precursor molecules from filamentous fungi,” said Mark Emalfarb, CEO of Dyadic.
“We believe that by using synthetic biology to further engineer and optimize the production of C1-cells to produce CBD, other cannabinoids and THC, will generate great interest in light of the burgeoning potential uses for CBD and other cannabinoids in animal and human health, including medical and recreational marijuana and cannabinoid products, such as CBD,” he added.
Joe Hazelton, chief business officer, said that as part of the company’s 2022 strategic operating plan, Dyadic is focused across three core business verticals: human health, with a focus on infectious diseases, including COVID-19; non-infectious diseases in human and animal health; and other biological products, including enzymes and metabolites.
“As we look at the year ahead, Dyadic intends to further advance and develop our pipeline of assets, both internally and through joint ventures, licensing, partnerships, and other collaborations,” Mr. Hazelton said.